New study aims to reduce bleeding and clotting risks in cancer surgery patients on blood thinners

NCT ID NCT07372716

Not yet recruiting Knowledge-focused Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management practices are safe and to improve future care for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: standardized perioperative anticoagulation management guideline
What this could lead to: If successful, this could lead to safer guidelines for managing blood thinners in cancer patients undergoing surgery, reducing bleeding and clotting complications.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may not apply to all cancer types or blood thinner regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation cancer Hemorrhage hemorrhagic disease neoplasm thrombotic disease venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) BLEEDING CANCER THROMBOSIS THROMBOSIS, DEEP VEIN VENOUS THROMBOEMBOLIC EVENT

More trials for these conditions

Other studies related to the condition(s) this trial covers.